Clinical manifestation and survival of patients with small-cell lung cancer.
Clinical manifestation and survival of patients with small-cell lung cancer.
复制标题
小细胞肺癌患者的临床表现和生存情况。
DOI：
--
复制
发表时间：
2004
影响因子：
--
通讯作者：
W. Tanomkiat
中科院分区：
文献类型：
--
作者：
K. Thammakumpee;S. Juthong;V. Viriyachaiyo;Warangkana Rittirak;W. Tanomkiat
客观化
目的探讨小细胞肺癌(SCLC)的临床表现、诊断性研究、治疗及生存率。
设计
回溯性研究。
材料和方法
回顾1999年1月1日至2003年12月31日期间，经组织学和/或细胞学证实、有足够的临床病史和生存记录的小细胞肺癌患者。根据退伍军人管理局肺癌研究小组(VALSG)对局限性和广泛性疾病的分期系统进行疾病的分期。
结果
本研究共纳入116例小细胞肺癌患者。小细胞肺癌在吸烟的老年男性中很常见。主要症状为咳嗽81%，体重减轻72%，呼吸困难67%。声音嘶哑和上腔静脉综合征(SVC综合征)的发生率分别为18%和17%。49例患者(42%)表现为局限期疾病，67例(58%)表现为广泛期疾病。30例患者(26%)单独接受化疗，23例患者(20%)单独接受放射治疗，33例患者(28%)接受放化综合治疗，30例患者(26%)接受支持治疗。顺铂联合依托泊苷方案化疗61例(97%)。化疗完全缓解12例(19%)，部分缓解20例(32%)。局限期疾病的中位生存期明显好于广泛期疾病患者(44周比22周)。接受化疗的患者显著提高了有限期和广泛期疾病的中位生存期。
结论
超过一半的小细胞肺癌患者表现为广泛期疾病。大多数患者接受了全身化疗。与广泛期疾病相比，局限期疾病患者对化疗的反应更好，生存时间更长。
OBJECTIVE
To assess the clinical manifestation, diagnostic investigation, treatment, and survival of patients with small-cell lung cancer (SCLC).
DESIGN
Retrospective study.
MATERIAL AND METHOD
Patients with histologically and/or cytologically proven SCLC, adequate medical record for clinical history, and survival between January 1, 1999 and December 31, 2003, were reviewed. The stage of disease at presentation was based on the Veterans' Administration Lung Cancer Study Group (VALSG) staging system of limited-stage and extensive-stage disease.
RESULTS
One hundred and sixteen evaluative SCLC patients were enrolled in the present study. SCLC was common in elderly men who smoked. Major symptoms were cough 81%, weight loss 72%, and dyspnea 67%. Hoarseness and superior vena cava syndrome (SVC syndrome) were present in 18% and 17% respectively. Forty-nine patients (42%) presented with limited-stage disease and 67 (58%) with extensive-stage disease. Thirty patients (26%) received chemotherapy alone, 23 patients (20%) received radiotherapy alone, 33 patients (28%) received combined chemoradiotherapy, and 30 patients (26%) received supportive treatment. A chemotherapy regimen of cisplatin combined with etoposide was used in 61 of 63 patients (97%). The overall response to chemotherapy was complete remission in 12 cases (19%), and partial response in 20 cases (32%). The median survival of limited-stage disease was significantly better than those with extensive-stage disease (44 weeks vs. 22 weeks). Patients with chemotherapy treatment had significantly improved median survival in both limited-stage and extensive-stage disease.
CONCLUSION
More than half of the SCLC patients presented in extensive-stage disease. The majority of the patients were treated with systemic chemotherapy. Patients with limited-stage disease had better response to chemotherapy and better survival than those with extensive-stage disease.